Literature DB >> 28329153

Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection.

Priyanka Uprety1, Kunjal Patel2, Brad Karalius2, Carrie Ziemniak3, Ya Hui Chen3, Sean S Brummel2, Suzanne Siminski4, Russell B Van Dyke5, George R Seage2, Deborah Persaud3.   

Abstract

BACKGROUND.: Early antiretroviral therapy (ART) limits proviral reservoirs, a goal for human immunodeficiency virus type 1 (HIV-1) remission strategies. Whether this is an immediate or long-term effect of virologic suppression (VS) in perinatal infection is unknown. METHODS.: We quantified HIV-1 DNA longitudinally for up to 14 years in peripheral blood mononuclear cells (PBMCs) among 61 perinatally HIV-1-infected youths in the Pediatric HIV/AIDS Cohort Study who achieved VS at different ages. Participants in group 1 (n = 13) were <1 year of age and in group 2 (n = 48) from 1 through 5 years of age at VS. Piecewise linear mixed-effects regression models assessed the effect of age at VS on HIV-1 DNA trajectories during VS. RESULTS.: In the first 2 years following VS, HIV-1 DNA levels decreased by -0.25 (95% confidence interval [CI], -.36 to -.13) log10 copies/million PBMCs per year and was faster with early VS by age 1 year compared with after age 1 (-0.50 and -0.15 log10 copies/million PBMCs per year, respectively). Between years 2 and 14 from VS, HIV-1 DNA decayed by -0.05 (95% CI, -.06 to -.03) log10 copies/million PBMCs per year and was no longer significantly different between groups. The estimated mean half-life of HIV-1 DNA from VS was 15.9 years and was shorter for group 1 compared to group 2 at 5.9 years and 18.8 years, respectively (P = .09). Adjusting for CD4 cell counts had no effect on decay estimates. CONCLUSIONS.: Early effective, long-term ART initiated from infancy leads to decay of HIV-1-infected cells to exceedingly low concentrations desired for HIV-1 remission strategies.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV-1 DNA decay; early ART.; perinatal HIV-1 infection

Mesh:

Substances:

Year:  2017        PMID: 28329153      PMCID: PMC5434384          DOI: 10.1093/cid/cix192

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

1.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.

Authors:  Jintanat Ananworanich; Thanyawee Puthanakit; Piyarat Suntarattiwong; Kulkanya Chokephaibulkit; Stephen J Kerr; Rémi Fromentin; Wendy Bakeman; Jintana Intasan; Apicha Mahanontharit; Sunee Sirivichayakul; Nicolas Chomont
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

4.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

Review 5.  Very early combination antiretroviral therapy in infants: prospects for cure.

Authors:  Kaitlin Rainwater-Lovett; Katherine Luzuriaga; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

6.  Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Authors:  Laurent Hocqueloux; Véronique Avettand-Fènoël; Sophie Jacquot; Thierry Prazuck; Eric Legac; Adeline Mélard; Mohamadou Niang; Catherine Mille; Gwenaël Le Moal; Jean-Paul Viard; Christine Rouzioux
Journal:  J Antimicrob Chemother       Date:  2013-01-20       Impact factor: 5.790

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

Authors:  Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors
Journal:  Clin Infect Dis       Date:  2014-07-29       Impact factor: 9.079

9.  Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants.

Authors:  Margaret McManus; Eric Mick; Richard Hudson; Lynne M Mofenson; John L Sullivan; Mohan Somasundaran; Katherine Luzuriaga
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

10.  HIV-1 DNA predicts disease progression and post-treatment virological control.

Authors:  James P Williams; Jacob Hurst; Wolfgang Stöhr; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Mary Carrington; Abdel Babiker; Jonathan Weber; Kersten K Koelsch; Anthony D Kelleher; Rodney E Phillips; John Frater
Journal:  Elife       Date:  2014-09-12       Impact factor: 8.140

View more
  16 in total

Review 1.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

2.  Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus.

Authors:  Marta Massanella; Thanyawee Puthanakit; Louise Leyre; Thidarat Jupimai; Panadda Sawangsinth; Mark de Souza; Piyarat Suntarattiwong; Pope Kosalarksa; Thitiporn Borkird; Suparat Kanjanavanit; Kulkanya Chokephaibulkit; Rawiwan Hansudewechakul; Witaya Petdachai; Julie L Mitchell; Merlin L Robb; Lydie Trautmann; Jintanat Ananworanich; Nicolas Chomont
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

3.  Differences in inducibility of the latent HIV reservoir in perinatal and adult infection.

Authors:  Adit Dhummakupt; Jessica H Rubens; Thuy Anderson; Laura Powell; Bareng As Nonyane; Lilly V Siems; Aleisha Collinson-Streng; Tricia Nilles; R Brad Jones; Vicki Tepper; Allison Agwu; Deborah Persaud
Journal:  JCI Insight       Date:  2020-02-27

Review 4.  The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV.

Authors:  Paolo Palma; Margaret McManus; Nicola Cotugno; Salvatore Rocca; Paolo Rossi; Katherine Luzuriaga
Journal:  Lancet HIV       Date:  2020-05       Impact factor: 12.767

5.  The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32-CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression.

Authors:  Adit Dhummakupt; Lilly V Siems; Dolly Singh; Ya Hui Chen; Thuy Anderson; Aleisha Collinson-Streng; Hao Zhang; Purvish Patel; Allison Agwu; Deborah Persaud
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

Review 6.  The pharmacological treatment of acute HIV infections in neonates.

Authors:  Louise Kuhn; Stephanie Shiau
Journal:  Expert Rev Clin Pharmacol       Date:  2017-11-03       Impact factor: 5.045

7.  Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.

Authors:  Margaret McManus; Jennifer Henderson; Anita Gautam; Robin Brody; Eric R Weiss; Deborah Persaud; Eric Mick; Katherine Luzuriaga
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

8.  Clinical validation of a quantitative HIV-1 DNA droplet digital PCR assay: Applications for detecting occult HIV-1 infection and monitoring cell-associated HIV-1 dynamics across different subtypes in HIV-1 prevention and cure trials.

Authors:  Laura Powell; Adit Dhummakupt; Lilly Siems; Dolly Singh; Yann Le Duff; Priyanka Uprety; Cheryl Jennings; Joseph Szewczyk; Ya Chen; Eleni Nastouli; Deborah Persaud
Journal:  J Clin Virol       Date:  2021-04-14       Impact factor: 14.481

9.  Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa.

Authors:  Faeezah Patel; Cara Thurman; Afaaf Liberty; Megan Burke; Renate Strehlau; Stephanie Shiau; Ashraf Coovadia; Elaine J Abrams; Avy Violari; Louise Kuhn
Journal:  J Acquir Immune Defic Syndr       Date:  2020-04-01       Impact factor: 3.771

10.  Quantitative HIV-1-specific antibodies as predictors of peripheral blood cell-associated HIV-1 DNA concentrations.

Authors:  Margaret McManus; Brad Karalius; Kunjal Patel; Deborah Persaud; Katherine Luzuriaga
Journal:  AIDS       Date:  2020-07-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.